Dr Elaine Elizabeth Olson, MD | |
100 Village Green Dr, #220, Lincolnshine, IL 60069-3095 | |
(847) 793-8890 | |
(847) 793-8894 |
Full Name | Dr Elaine Elizabeth Olson |
---|---|
Gender | Female |
Speciality | Pain Medicine - Interventional Pain Medicine |
Location | 100 Village Green Dr, Lincolnshine, Illinois |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1619963311 | NPI | - | NPPES |
21621708 | Other | IL | BLUECROSS BS |
21621708 | Other | IL | BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0014X | Pain Medicine - Interventional Pain Medicine | (Illinois) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Elaine Elizabeth Olson, MD Po Box 1226, Park Ridge, IL 60068 Ph: (847) 793-8890 | Dr Elaine Elizabeth Olson, MD 100 Village Green Dr, #220, Lincolnshine, IL 60069-3095 Ph: (847) 793-8890 |
News Archive
A team of Spanish scientists, which includes several researchers from the University of Granada, has confirmed that there is a relation between the levels of certain environmental pollutants that a person accumulates in his or her body and their level of obesity. Subjects with more pollutants in their organisms present besides higher levels of cholesterol and triglycerides, which are important risk factors for cardiovascular disease.
Filipinos are "struggling to live in flooded suburbs or crowded shelters one month after devastating rains began pounding the Philippines, and officials warn no quick fix is in sight," Agence France-Presse reports. According to the WHO, 1.43 million people, "mostly in and around Manila, continue to endure a dangerous existence living in flooded districts" (Morella, 10/26).
C.S. Lewis, the famous author and Oxford academic, once proclaimed "You can't get a cup of tea big enough or a book long enough to suit me." We sip it with toast in the morning, enjoy it with sweets and biscuits in the afternoon, and relax with it at the end of the day.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer.
› Verified 1 days ago